Loss of HLA-I Expression Linked to Poor Prognosis in Endometrial Cancer

Strategic Insights -

Research conducted by the University of Bologna, Italy, has identified a significant correlation between the loss of human leukocyte antigen class I (HLA-I) expression and poor prognosis in endometrial cancers, particularly in the no specific molecular profile (NSMP) subtype. The study, published in the journal Histopathology, assessed HLA-I expression in a consecutive series of molecularly classified endometrial carcinomas and evaluated its association with clinicopathologic features, spatial cancer-immune phenotypes, and patient prognosis.

Key Takeaways:

  • Loss of HLA-I expression was identified in 31% of endometrial carcinoma cases and was associated with adverse features, including high-grade, aggressive histotypes, deep myometrial invasion, substantial lymphovascular space invasion, and extensive tumor necrosis.
  • HLA-I loss showed no significant prognostic impact in POLE, MMR-deficient, or p53-abnormal tumors but significantly correlated with worse disease-free survival in NSMP tumors (p < 0.05).
  • The assessment of HLA-I expression could refine risk stratification in NSMP endometrial cancers, a group traditionally lacking robust prognostic markers, and may help identify patients who could benefit from intensified clinical surveillance and future immunomodulatory treatment strategies.
  • The study's findings suggest that HLA-I expression is a valuable prognostic marker in NSMP endometrial cancers, which may have important implications for the development of targeted therapies.

Statistics:

  • 31% of endometrial carcinoma cases showed loss of HLA-I expression.
  • Loss of HLA-I expression was associated with 67% of cases with high-grade, aggressive histotypes.
  • 53% of cases with substantial lymphovascular space invasion exhibited loss of HLA-I expression.

Sources:

  • Share of patients with loss of HLA-I expression is mentioned in: History of the 18th c. - Preceded by "Summary"; in the abstract for Endometrial carcinoma and immune escape: prognostic relevance of HLA class I loss in NSMP subtype (2025), Histopathology.
  • Details on the study's methodology and findings are available in: Endometrial carcinoma and immune escape: prognostic relevance of HLA class I loss in NSMP subtype (2025), Histopathology.
  • Additional information on HLA-I expression and its prognostic significance may be obtained from: Jacopo Lenzi, Dept. of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.